SCHEMBL176864

SCHEMBL176864

O=C(c1n[nH]c2c1CCCCC2=Cc1ccc(Cl)cc1)N1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 3/20 0.41
LMNA P02545 1/20 0.39
RAB9A P51151 3/20 0.39
GAA P10253 1/20 0.39
ALPL P05186 3/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C1 Q04828 1/20 0.39
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
ACHE P22303 1/20 0.36
PAX8 Q06710 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL176863 1.00 NPC1 (0.43) NPC1HTTMAPTLMNARAB9A
SCHEMBL176623 0.84 NPC1 (0.46) NPC1HTT
SCHEMBL176622 0.84 NPC1 (0.46) NPC1HTT
SCHEMBL300513 0.84 NPC1 (0.46) NPC1HTTMAPTLMNARAB9A
SCHEMBL4915235 0.84 NPC1 (0.46) NPC1HTTMAPTLMNARAB9A
SCHEMBL14258958 0.83 NPC1 (0.47) NPC1HTTLMNARAB9AAKR1C3
SCHEMBL4218058 0.78 AKR1C3 (0.40) HTTMAPTAKR1C3AKR1C1MEN1
SCHEMBL176669 0.78 SMN1; SMN2 (0.46) NPC1HTTMAPTAKR1C3AKR1C1
SCHEMBL300698 0.78 LIPE (0.48) NPC1HTTAKR1C3AKR1C1
SCHEMBL176670 0.78 SMN1; SMN2 (0.46) NPC1HTTMAPTAKR1C3AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378096-B2 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-19 US claimed
EP-1937259-B1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-11-23 EP claimed
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-20 US claimed
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 US claimed
EP-1937259-B1 HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-11-23 EP disclosed
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070968-A1 Hexahydro-Cycloheptapyrazole Cannabinoid Modulators CNR2, CNR1, FAAH NPC1 601/4885HTT 440/4885MAPT 1737/4885
US-20070123578-A1 Hexahydro-cycloheptapyrazole cannabinoid modulators CNR2, CNR1, FAAH NPC1 601/4885HTT 440/4885MAPT 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.